Improved reg. allow price succession of transfer products

By Chon, Seung-Hyun | translator Alice Kang

21.05.31 06:00:55

가나다라 0

Organon Korea’s ‘Ezetrol’ newly listed at highest price… maintaining its price through transfer/acquisition

Avoided drug price cuts using the product transfer/acquisition regulations newly added in January

Daewoong Bio, Alvogen and Celltrion also lists transferred/acquired products at highest price

Drug price succession in transferred pharmaceutical products has been increasing. As the stepped pricing system is no longer applied to drugs that are relisted due to change of licensees, companies have been actively engaged in the transfer of their products. Some products have seen a twofold increase in their price compared to when the stepped pricing system was applied.

According to the Ministry of Health and Welfare (MOHW) on the 30th, Organon Korea’s ‘Ezetrol tab.’ will be listed at a ceiling price of 744 won. Ezetrol (ezetimibe) originally used to be owned by MSD Korea.

As the license holder was changed to Organon Korea, a new spin-off of MSD Korea, the drug had to be newly listed

Chon, Seung-Hyun(1000@dailypharm.com)

If you want to see the full article, please JOIN US (click)